Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions

Zimmerman, R. L.; Fogt, D M Franz; Goonewardene, Shanth

doi:10.1002/1097-0142(20000825)90:4<230::aid-cncr5>3.0.co;2-6

Cited by 15 publications

(9 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The combination of mucicarmine and Glut-1 detected 81% of breast tumors. Although respectable, this performance is less than that of other individual immunostains such as CA15-3 and BCA-225 (10,23). Of the 16 breast carcinoma cases studied with both Glut-1 and CA15-3, 100% stained with CA15-3, compared with 10 of 16 (63%) for Glut-1.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Glucose Transporter Glut-1 Is of Limited Value for Detecting Breast Carcinoma in Serous Effusions

2001

Self Cite

View full text Add to dashboard Cite

Diagnosing breast carcinoma that has metastasized to body cavity fluids can be difficult. Recently, immunostaining for the facultative glucose transporter Glut-1 has been described as a sensitive and specific means of detecting carcinomas in effusions. However, only five cases of breast carcinoma were studied. We examined Glut-1 specifically as a means of detecting breast carcinoma in effusion cytology. Using avidin-biotin immunocytochemistry, cell block material from 31 cases of breast carcinoma metastatic to body cavity effusions and 33 cases of benign effusions were studied. All cases were immunostained with the Glut-1 antibody. An additional set of slides from these same cases was stained for mucin using the Mayer's mucicarmine technique. Slides were graded for percentage of cells exhibiting immunoreactivity for Glut-1 or for the presence of mucin. Results of staining for both Glut-1 alone and in combination with mucicarmine were compared between the benign and malignant groups. Of the breast cancer cases, 19 of 31 (61%) were immunoreactive for Glut-1, and 25 of 31 (81%) were positive for either Glut-1 or mucicarmine. One of the 33 (3%) benign cases was immunoreactive for Glut-1, and none were positive for mucin. These data suggest that using Glut-1 as a single immunostain or in conjunction with mucicarmine is a specific but modestly sensitive means of detecting breast carcinoma in this cytologic setting.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The medical history of the benign cases is summarized in Table 1. Some of these cases have been reported previously (10,12,22,23). The cell blocks had cellular material present on the last hematoxylin and eosin-stained slide cut.…”

Section: Methodsmentioning

confidence: 99%

Glucose Transporter Glut-1 Is of Limited Value for Detecting Breast Carcinoma in Serous Effusions

2001

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some of these cases have been reported previously. [10][11][12] In all, 47 cases were diagnosed as benign reactive mesothelium; the remaining cases were malignant. The malignant cases were primarily adenocarcinomas with a small number of other carcinomas and mesotheliomas.…”

Section: Methodsmentioning

confidence: 99%

The β subunit of human chorionic gonadotropin lacks specificity for malignant cells in serous effusions

Zimmerman

Fogt

2004

Modern Pathology

Self Cite

View full text Add to dashboard Cite

The cytologic diagnosis of malignancy is frequently straightforward. For difficult cases, multiple immunostains and immunostain panels have been investigated without consensus. b-human chorionic gonadotropin (hCG) has been reportedly expressed in malignancies, but not in normal tissue. HCG also has been reported as a specific marker of metastases in serous fluids when detected with laboratory assays. We investigated the clinical utility of hCG in this cytologic setting. A total of 97 cases of benign and malignant effusions were studied. Each case was immunostained with monoclonal hCG using the avidin-biotin technique and diaminobenzidine as a chromogen. Additionally, a mucicarmine stain was performed on most cases. Cases were evaluated for hCG expression and mucin in a blinded fashion. After the cases were reviewed, the diagnoses were unblinded and staining patterns were evaluated. Of the 47 benign cases studied, 23 (49%) exhibited immunoreactivity to hCG in at least 5% of mesothelial cells present. In contrast, 28 of 44 (64%) adenocarcionomas exhibited a similar degree of immunostaining. In all, 21 (48%) of the adenocarcinomas were also positive for mucin; five of these mucin-positive cases were negative for hCG. The combination of mucin and hCG detected 33 of 44 (75%) adenocarcinomas. We conclude that hCG lacks the specificity for malignant cells to be of clinical use in effusion cytology.

show abstract

“…It was found to be overexpressed in many different epithelial tumors including breast and lung cancers. MUC1 related tumor antigens including CA15.3 and CA27.29, which correspond to different glycosylated forms of MUC1 protein (Cheung et al, 2000;Zimmerman et al, 2000) can be detected in the sera of cancer patients, but not in normal controls (Marth and Varki, 1999). It has been hypothesized that the nonglycosylated form of MUC1, only detected in breast cancer, may play a role in the initial attachment of carcinoma cells to tissues at distant sites, facilitating establishment of metastatic foci (Ciborowski and Finn, 2002).…”

Section: Tumor Markers For Breast Cancermentioning

confidence: 99%

Human Small Breast Epithelial Mucin: The Promise of a New Breast Tumor Biomarker

Hubé¹,

Mutawe²,

Leygue³

et al. 2004

dna cell biol

View full text Add to dashboard Cite

Breast cancer remains one of the most frequently diagnosed cancers today. In developed countries, one in eight women is expected to present with breast cancer within her lifetime and an estimated 1,000,000 cases are detected each year worldwide (Canadian Cancer Statistics, http://www.cancer.ca/vgn/images/ portal/cit_86751114/14/33/1959864 11niw_stats2004_en.pdf). For women with recurrent disease, the median time of survival is about 2 years. Despite optimal surgery, adjuvant irradiation, hormonal treatment, and chemotherapy, approximately 30% of patients with localized breast cancer finally develop distant metastases. Early detection, which enables intervention at a localized and potentially curable stage, remains a central goal in breast cancer treatment. Indeed, the 5-year survival rate for women with breast cancer has been shown to increase dramatically when the disease is diagnosed at an early stage: from less than 25% in women with disseminated cancer to about 75% in patients with regional disease and over 95% in women with a localized tumor (Breast Cancer Facts and Figures, 2001-2002, http://www.cancer.org/downloads/STT/BrCaFF 2001.pdf). Unfortunately, only 60% of all breast cancers are diagnosed at a local stage. Any improvement in early detection through identification of tumor biomarkers would have a significant impact on reducing overall breast cancer mortality.

show abstract

Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions

Cited by 15 publications

References 18 publications

Glucose Transporter Glut-1 Is of Limited Value for Detecting Breast Carcinoma in Serous Effusions

Glucose Transporter Glut-1 Is of Limited Value for Detecting Breast Carcinoma in Serous Effusions

The β subunit of human chorionic gonadotropin lacks specificity for malignant cells in serous effusions

Human Small Breast Epithelial Mucin: The Promise of a New Breast Tumor Biomarker

Contact Info

Product

Resources

About